Why denosumab obtains a survival benefit over zoledronic acid in bone metastatic lung cancer patients?

J Thorac Oncol. 2013 Aug;8(8):e79. doi: 10.1097/JTO.0b013e318293e443.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Neoplasms / mortality*
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Imidazoles / therapeutic use*
  • Lung Neoplasms / mortality*
  • Male

Substances

  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles